Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 2Neurofibroma, Plexiform 2Peripheral Nervous System Diseases 1Neoplasms, Nerve Tissue 1Heredodegenerative Disorders, Nervous System 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Surveys and Questionnaires 1Hydroxychloroquine 1Glutamine 1Acupuncture Therapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Peripheral Nervous System Diseases × AZD 6244 × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡